Sanofi recently announced that the FDA approved its new long-acting insulin pen – Toujeo Max SoloStar. This pen holds 900 units and provides a maximum 160 units per injection. Toujeo is already sold in 1.5mL SoloStar prefilled pens, which contain 450 units per 3-count pack.
Toujeo is a long-acting insulin analog, and it has been shown to help adults with diabetes to improve glycemic control. The Toujeo Max SoloStar offers a higher capacity, and with the ability to provide a dose of 160 units, it could reduce the number of pens a patient uses. Additionally, this new delivery method could reduce the number of injections needed to deliver the proper dose of insulin glargine to the patient.
Patients and healthcare practitioners should be on the look for the prefilled pens for the Max SoloStar, which are predicted to launch later in 2018 as 2-count packages.
These findings were published in eMPR on March 27, 2018.